🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Last week, with @KyowaKirin_US, we announced that we submitted a new drug application (NDA) for our investigational menin inhibitor for the treatment of adult patients with R/R NPM1-m #AML to the U.S. FDA . Learn more: ir.kuraoncology.com/news-releases/…

#TeamKura stands together in support of those impacted by #AML. On #WorldAMLAwarenessDay, we reaffirmed our commitment to patients—advancing research, supporting advocacy, and working toward better outcomes. Learn more: kuraoncology.com/perspectives/a…

We are built for life— driven by purpose, dedicated to scientific excellence, and committed to helping patients with cancer lead better, longer lives. With strong financials, we're striving to deliver on our commitment. Read our 2024 Annual Report: ir.kuraoncology.com/financial-info…

Today we announced our Q1 2025 #earnings, detailing updates on business and pipeline milestones as we approach #ASCO25. View the full release: ir.kuraoncology.com/news-releases/… Tune in to our investor webcast call today at 4:30 p.m. ET: ir.kuraoncology.com/events/event-d…

We recently announced the first patients have been dosed in our KOMET-015 Phase 1 dose-escalation study of our #menin inhibitor in combination with imatinib for patients with advanced #GIST after imatinib failure. Learn more in the press release: ir.kuraoncology.com/news-releases/…

#TeamKura are finalists for the Achievement in Operational Excellence to Deliver Business Transformation award at the Business Transformation & Operational Excellence Awards, in partnership with the Global BTOPEX Summit! Stay tuned and read more: btopex.com/awards/?srslti…

During #AAPIHeritageMonth, #TeamKura honors the rich history, culture and contributions of Asian American and Pacific Islander communities and celebrate those shaping the future of science. Hear more from Yahu A. Liu, Ph.D., Executive Director, Medicinal Chemistry.

Kura CEO Troy Wilson, Ph.D., J.D. will participate in a fireside chat at the Bank of America 2025 Healthcare Conference this week, sharing the latest developments on our pipeline and programs. Learn more & access the webcast: ir.kuraoncology.com/news-releases/…

We’re presenting the full analysis of our Phase 1b/2 data from our KOMET-001 study in patients with R/R NPM1-m #AML, as well as a Phase 1a/1b trial-in-progress poster from our KOMET-015 study in #GIST at the upcoming ASCO Annual Meeting. More: ir.kuraoncology.com/news-releases/… #ASCO25

Our very own Troy Wilson, Ph.D., J.D. is an Entrepreneur Of The Year® 2025 Pacific Southwest finalist! EY honors business leaders for their ingenuity, courage and entrepreneurial spirit. Join us in congratulating Troy for his outstanding achievement.

This #NationalCancerResearchMonth, we celebrate the science and collaboration driving progress in #cancer care. Hear our CSO Francis Burrows, Ph.D., explain our translational research approach rooted in patient needs and a commitment to maximizing clinical impact. #NCRM25 AACR

This #NCSD2025, we honor the strength of those living with and beyond cancer. Your resilience drives our mission, and we’re working for you every day. Learn more about our commitment: kuraoncology.com/about-us/#our-… Cancer Survivors Day

#NEWS: The U.S. FDA has accepted our New Drug Application for our investigational menin inhibitor in adults with relapsed or refractory NPM1-mutant #AML. Learn more: ir.kuraoncology.com/news-releases/… @KyowaKirin_US

Results from our KOMET-001 Phase 2 registration-directed study of our investigational menin inhibitor for patients with R/R NPM1-m acute myeloid leukemia (#AML) were presented at #ASCO25. Learn more in the PR & join our investor webcast: ir.kuraoncology.com/news-releases/…

That’s a wrap on #ASCO25! We were pleased to share the latest on our registration-directed KOMET-001 study and connecting with so many of you in person. Catch up on our investor event replay here: ir.kuraoncology.com/events/event-d…

Congratulations to #TeamKura co-founder, President & CEO Troy Wilson, Ph.D., J.D. for being named an Entrepreneur Of The Year® 2025 Pacific Southwest Award winner! Thank you for all you do, Troy! #EOYUS #EOYPACSW

#EHA2025: We shared updated KOMET-007 data for newly diagnosed #AML, an encore KOMET-001 poster, and a trial-in-progress poster of our #GIST program. See the press release & join our live webcast next week: ir.kuraoncology.com/news-releases/…

Thanks to all who joined us at #EHA2025! We’re energized by our conversations and proud to share our latest progress across our pipeline. Watch our investor event replay here: ir.kuraoncology.com/events/event-d…